Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
In the Phase I clinical trial, nausea was dose-limiting at 0.025 mg/kg (approximately 1.75 mg for a 70 kg person) notably, this is the same dose later used for PT-141's FDA approval (Dorr et al., 1996)
Antibody drug conjugates: lessons from 20 years of clinical experience
These results suggested that GGT was the most important enzyme responsible for GSH degradation and that deletion of both ggt and pepT could significantly suppress the GSH degradation
No published trials compare outcomes between standard-start and loading-dose regimens
The same molecule moves through nicer doors too
US$ 22.66
US$ 25.71
US$ 29.20
US$ 24.71
US$ 20.87
